[go: up one dir, main page]

MX2020001875A - Forma polimorfica de tg02. - Google Patents

Forma polimorfica de tg02.

Info

Publication number
MX2020001875A
MX2020001875A MX2020001875A MX2020001875A MX2020001875A MX 2020001875 A MX2020001875 A MX 2020001875A MX 2020001875 A MX2020001875 A MX 2020001875A MX 2020001875 A MX2020001875 A MX 2020001875A MX 2020001875 A MX2020001875 A MX 2020001875A
Authority
MX
Mexico
Prior art keywords
acid addition
addition salts
free base
polymorphic forms
crystalline polymorphic
Prior art date
Application number
MX2020001875A
Other languages
English (en)
Inventor
Tracy Parrott
Robert K Mansfield
Original Assignee
Tragara Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tragara Pharmaceuticals Inc filed Critical Tragara Pharmaceuticals Inc
Publication of MX2020001875A publication Critical patent/MX2020001875A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente descripción proporciona formas polimórficas cristalinas de base libre de TG02 y sales de adición de ácido de TG02, composiciones farmacéuticas que comprenden formas polimórficas cristalinas de base libre de TG02 y sales de adición de ácido de TG02, y métodos para tratar cáncer y otras enfermedades en un paciente con formas polimórficas cristalinas de base libre de TG02 y sales de adición de ácido de TG02.
MX2020001875A 2017-08-18 2018-08-17 Forma polimorfica de tg02. MX2020001875A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762547157P 2017-08-18 2017-08-18
PCT/US2018/000264 WO2019035985A1 (en) 2017-08-18 2018-08-17 POLYMORPHIC FORM OF TG02

Publications (1)

Publication Number Publication Date
MX2020001875A true MX2020001875A (es) 2020-07-29

Family

ID=65359869

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001875A MX2020001875A (es) 2017-08-18 2018-08-17 Forma polimorfica de tg02.

Country Status (14)

Country Link
US (4) US10544162B2 (es)
EP (2) EP3668876B1 (es)
JP (1) JP7250764B2 (es)
KR (1) KR102758037B1 (es)
CN (1) CN111372934B (es)
AU (1) AU2018317865B2 (es)
CA (1) CA3073270A1 (es)
ES (1) ES2977589T3 (es)
IL (1) IL272697B2 (es)
MX (1) MX2020001875A (es)
RU (1) RU2020111019A (es)
SG (1) SG11202001441WA (es)
TW (1) TWI785098B (es)
WO (1) WO2019035985A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX387283B (es) 2016-03-24 2025-03-18 Cothera Biosciences Inc Tratamiento del cancer con tg02.
TWI785098B (zh) 2017-08-18 2022-12-01 開曼群島商科賽睿生命科學公司 Tg02之多晶型
EP3958854B1 (en) * 2019-04-22 2025-06-04 University of Pittsburgh - of The Commonwealth System of Higher Education Tg02 for use in treating gliomas in pediatric subjects
CN110664760B (zh) * 2019-10-28 2020-10-23 浙江大学 一种负载vegfr靶向抑制剂的药物载体及其制备方法和应用
WO2024031406A1 (en) * 2022-08-10 2024-02-15 Xiang Li Idh mutations as biomarkers for zotiraciclib therapy
CN115429793A (zh) * 2022-08-15 2022-12-06 复旦大学附属中山医院 一种化合物在制备治疗肝细胞癌药物中的应用
CN115305251B (zh) * 2022-08-30 2023-06-27 中国农业科学院北京畜牧兽医研究所 Ap2-mybl2分子模块在调控原花色素生物合成中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1982001011A1 (en) 1980-09-24 1982-04-01 Corp Cetus Diagnostic method and probe
US4582788A (en) 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
DE3381518D1 (de) 1982-01-22 1990-06-07 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US4683194A (en) 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US6605712B1 (en) 1990-12-20 2003-08-12 Arch Development Corporation Gene transcription and ionizing radiation: methods and compositions
WO1998042752A1 (en) 1997-03-21 1998-10-01 Brigham And Women's Hospital Inc. Immunotherapeutic ctla-4 binding peptides
US6808710B1 (en) 1999-08-23 2004-10-26 Genetics Institute, Inc. Downmodulating an immune response with multivalent antibodies to PD-1
ATE354655T1 (de) 1999-08-24 2007-03-15 Medarex Inc Humane antikörper gegen ctla-4 und deren verwendungen
WO2003070887A2 (en) 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF POLYCOMB GROUP PROTEIN EZH2 GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2206517B1 (en) 2002-07-03 2023-08-02 Ono Pharmaceutical Co., Ltd. Immunopotentiating compositions comprising anti-PD-L1 antibodies
BRPI0607809A2 (pt) * 2005-02-18 2009-06-13 Abraxis Bioscience Inc uso de uma composição compreendendo nanopartìculas, composição e kit
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
PT1951730E (pt) 2005-11-16 2010-08-27 S Bio Pte Ltd Derivados de pirimidina ligados a heteroalquilo
EP3243814B1 (en) 2007-04-16 2018-10-17 AbbVie Inc. 7-substituted indole as mcl-1 inhibitors
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
GB0806652D0 (en) 2008-04-11 2008-05-14 Glaxo Group Ltd Anhydrous crystal form of orvepitant maleate
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
PL2350129T3 (pl) 2008-08-25 2015-12-31 Amplimmune Inc Kompozycje antagonistów PD-1 i sposoby stosowania
EP4331604B9 (en) 2008-12-09 2025-07-23 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2418955A4 (en) * 2009-04-15 2012-11-21 Poniard Pharmaceuticals Inc ORAL PICOPLATIN ANTITUMOR THERAPY WITH HIGH BIOAVAILABILITY
JP4965623B2 (ja) 2009-09-30 2012-07-04 インターナショナル・ビジネス・マシーンズ・コーポレーション 所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム
ES2632548T3 (es) * 2010-02-05 2017-09-14 Tragara Pharmaceuticals, Inc. Formas de estado sólido de los inhibidores de la quinasa macrocíclica
WO2011103016A2 (en) 2010-02-19 2011-08-25 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
WO2011127202A2 (en) 2010-04-06 2011-10-13 Fred Hutchinson Cancer Research Center Methods for identifying and using inhibitors of casein kinase 1 epsilon isoform for inhibiting the growth and/or proliferation of myc-driven tumor cells
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
AU2013201121A1 (en) 2011-09-20 2013-04-04 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
CA2850570A1 (en) 2011-09-30 2013-04-04 Glaxosmithkline Llc Methods of treating cancer
ES2808152T3 (es) 2011-11-28 2021-02-25 Merck Patent Gmbh Anticuerpos anti-PD-L1 y usos de los mismos
ES2718900T3 (es) 2012-03-12 2019-07-05 Epizyme Inc Inhibidores de EZH2 humana y métodos de uso de los mismos
SG10201700698WA (en) 2012-05-15 2017-02-27 Bristol Myers Squibb Co Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
EP2879709B1 (en) 2012-07-31 2020-01-08 The Brigham and Women's Hospital, Inc. Modulation of the immune response
US9688665B2 (en) 2012-10-15 2017-06-27 Epizyme, Inc. Methods of treating cancer
TR201816077T4 (tr) 2013-02-21 2018-11-21 Pfizer Seçici bir cdk4/6 inhibitörünün katı formları.
ES2808654T3 (es) 2013-03-15 2021-03-01 Glaxosmithkline Ip Dev Ltd Proteínas de unión anti-LAG-3
IL292193B2 (en) 2013-09-11 2024-11-01 Medimmune Ltd Anti-b7-h1 antibodies for treating tumors
US20150250853A1 (en) 2014-03-07 2015-09-10 University Health Network Methods and compositions for modifying the immune response
LT3116909T (lt) 2014-03-14 2020-02-10 Novartis Ag Antikūno molekulės prieš lag-3 ir jų panaudojimas
NZ723859A (en) 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
MX387283B (es) 2016-03-24 2025-03-18 Cothera Biosciences Inc Tratamiento del cancer con tg02.
TWI785098B (zh) 2017-08-18 2022-12-01 開曼群島商科賽睿生命科學公司 Tg02之多晶型

Also Published As

Publication number Publication date
CA3073270A1 (en) 2019-02-21
TWI785098B (zh) 2022-12-01
IL272697B1 (en) 2023-08-01
EP4364741A2 (en) 2024-05-08
AU2018317865A1 (en) 2020-03-19
EP3668876B1 (en) 2024-01-24
CN111372934A (zh) 2020-07-03
EP3668876A4 (en) 2021-04-28
US20190055263A1 (en) 2019-02-21
JP2020531463A (ja) 2020-11-05
KR20200078481A (ko) 2020-07-01
SG11202001441WA (en) 2020-03-30
US20200262843A1 (en) 2020-08-20
AU2018317865B2 (en) 2023-03-16
US20240254142A1 (en) 2024-08-01
RU2020111019A (ru) 2021-09-20
TW201920199A (zh) 2019-06-01
CN111372934B (zh) 2024-04-26
EP3668876A1 (en) 2020-06-24
US10544162B2 (en) 2020-01-28
JP7250764B2 (ja) 2023-04-03
KR102758037B1 (ko) 2025-01-22
RU2020111019A3 (es) 2022-03-18
IL272697B2 (en) 2023-12-01
US20240254141A1 (en) 2024-08-01
IL272697A (en) 2020-04-30
WO2019035985A1 (en) 2019-02-21
EP4364741A3 (en) 2024-07-03
ES2977589T3 (es) 2024-08-27
US12043630B2 (en) 2024-07-23

Similar Documents

Publication Publication Date Title
MX2020001875A (es) Forma polimorfica de tg02.
ZA202004764B (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2020009780A (es) Compuestos de inhibidor de autotaxina.
GEAP201914679A (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX363347B (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
NZ752587A (en) Lsd1 inhibitors and medical uses thereof
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
EA201691918A1 (ru) Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
EA033446B1 (ru) Гетероциклическое соединение для лечения дегенерации желтого пятна и/или болезни штаргардта
MY201580A (en) Use of ezh2 inhibitor combined with btk inhibitor in preparing drug for treating tumor
PH12018501237A1 (en) Isoindole compounds
MX2017007259A (es) Composiciones de sales metalicas.
MX2015012720A (es) Sales basicas de adicion de nitroxolina y usos de las mismas.
MX2020000135A (es) Nuevos compuestos de quinolinona.
EA033423B1 (ru) Циклопропанбензофуранилпиридопиразиндионы
MX2015013155A (es) Formulaciones farmaceuticas de la familia de la tetrandrina y metodo.
MX2016014699A (es) (s)-pirlindol o sus sales farmaceuticamente aceptables para uso en medicina.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2018004696A (es) Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos.
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.